Zydus Lifesciences Ltd
Zydus Lifesciences Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #56 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
FY27 guidance: Strong double-digit overall revenue growth with mid-teens growth expected in India business. Zydus Lifesciences projects strong double-digit revenue growth for FY27, with continued mid-teens growth in the India business and single-digit growth internationally.
From Zydus Lifesciences Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- FY27 guidance: Strong double-digit overall revenue growth with mid-teens growth expected in India business.
- India formulation business: 20% growth in branded portfolio; chronic therapies and innovation portfolios driving sustainable momentum.
- International markets (EM and Europe): Continued strong growth with new market entries scaling faster than expected.
- US business: Single-digit growth expected this year, with potential for double-digit growth in FY28 driven by pipeline and branded product scaling.
- Consumer Wellness: Strong double-digit growth anticipated, continuing 25% like-to-like growth internationally.
- Medical devices: Growth through investment in focused therapies and differentiation.
- Medium term: Branded portfolio expected to exceed two-thirds of total revenue, driving improved growth and profitability.
2 more points from Zydus Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Zydus Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex guidance for the full year is around ₹1,500-₹1,600 crores.
- Investments include:
- Expansion of existing facilities: Moraiya, Goa, Baddi, Unit-2 and Unit-3 at SEZ.
- New formulation R&D center for development.
- One-time land acquisition for wellness business expansion.
- New CAR-T facility for biologics.
- New vaccines DS (Drug Substance) facility.
- Continued investment in Zylidac.
- Saro (Saroglitazar US launch) will require investments primarily in FY27 and FY28, with build-out phase for first 2 years post-launch in FY28.
2 more points from Zydus Lifesciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zydus Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Zydus Lifesciences Ltd's call on order book
Create a free account to keep reading this call
Zydus Lifesciences Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.6K Cr, net profit ₹1.3K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zydus Lifesci.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zydus Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zydus Lifesciences Ltd Q1 FY27 results?
FY27 guidance: Strong double-digit overall revenue growth with mid-teens growth expected in India business. Zydus Lifesciences projects strong double-digit revenue growth for FY27, with continued mid-teens growth in the India business and single-digit growth internationally.
What is Zydus Lifesciences Ltd share price analysis?
Zydus Lifesciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 22.9 with a market cap of ₹111,720 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zydus Lifesciences Ltd planning capital expenditure?
Capex guidance for the full year is around ₹1,500-₹1,600 crores.
Keep Zydus Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.